Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy

Journal of Urology

Volumn 186, Issue 1, 2011, Pages 191-197

  Page, Stephanie T ^a,b   Hirano, Lianne ^c,d   Gilchriest, Janet ^c,d   Dighe, Manjiri ^b   Amory, John K ^a   Marck, Brett T ^c,d   Matsumoto, Alvin M ^a,c,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Veterans Affairs Puget Sound Health Care System Seattle Division ^*  (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

5 alpha reductase inhibitors; dihydrotestosterone; prostate; testosterone

Indexed keywords

ANDROSTANOLONE; ANDROSTENEDIONE; DUTASTERIDE; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ANDROGEN THERAPY; ARTICLE; BREAST TENDERNESS; COLITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FATALITY; ECZEMA; ESTRADIOL BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPOGONADISM; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL;

5-ALPHA REDUCTASE INHIBITORS; AGED; AGED, 80 AND OVER; ANDROGENS; AZASTEROIDS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; ORGAN SIZE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; TESTOSTERONE;

EID: 79958287449     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.03.026     Document Type: Article

References (26)

1. G. Schatzl, C. Brssner, and S. Schmid Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function The Prostate Study Group of the Austrian Society of Urology Urology 55 2000 397
2. W.M. Garraway, G.N. Collins, and R.J. Lee High prevalence of benign prostatic hypertrophy in the community Lancet 338 1991 469
3. D.A. Gruenewald, and A.M. Matsumoto Testosterone supplementation therapy for older men: potential benefits and risks J Am Geriatr Soc 51 2003 101
4. S. Beg, L. Al-Khoury, and G.R. Cunningham Testosterone replacement in men Curr Opin Endocrinol Diabetes Obes 15 2008 364
5. S. Bhasin, G.R. Cunningham, and F.J. Hayes Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 95 2010 2536
6. B. Jin, A.J. Conway, and D.J. Handelsman Effects of androgen deficiency and replacement on prostate zonal volumes Clin Endocrinol (Oxf) 54 2001 437
7. H.M. Behre, J. Bohmeyer, and E. Nieschlag Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls Clin Endocrinol (Oxf) 40 1994 341
8. J.K. Amory, N.B. Watts, and K.A. Easley Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone J Clin Endocrinol Metab 89 2004 503
9. M. Marberger, C.G. Roehrborn, and L.S. Marks Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia J Clin Endocrinol Metab 91 2006 1323
10. M. Marberger Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia Nat Clin Pract Urol 3 2006 495
11. G.L. Andriole, D.G. Bostwick, and O.W. Brawley Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192
12. I.M. Thompson, P.J. Goodman, and C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215
13. L.S. Marks, and S.A. Kaplan Should testosterone replacement be given to men with large prostates? J Urol 182 2009 2109
14. W. Gao, and J.T. Dalton Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase? Mol Interv 7 2007 10
15. M.Y. Roth, S.T. Page, and K. Lin Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency J Clin Endocrinol Metab 95 2010 3806
16. F. Debruyne, J. Barkin, and P. van Erps Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia Eur Urol 46 2004 488
17. V. Luu-The, A. Blanger, and F. Labrie Androgen biosynthetic pathways in the human prostate Best Pract Res Clin Endocrinol Metab 22 2008 207
18. S. Kalinchenko, E.L. Vishnevskiy, and A.N. Koval Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study Aging Male 11 2008 57
19. C.G. Roehrborn, J.D. McConnell, and B. Saltzman Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes Eur Urol 42 2002 1
20. E.D. Crawford, S.S. Wilson, and J.D. McConnell Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo J Urol 175 2006 1422
21. C.G. Roehrborn, J.D. McConnell, and M. Lieber Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia PLESS Study Group Urology 53 1999 473
22. A.W. Roddam, N.E. Allen, and P. Appleby Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies J Natl Cancer Inst 100 2008 170
23. G.A. Laughlin, E. Barrett-Connor, and J. Bergstrom Low serum testosterone and mortality in older men J Clin Endocrinol Metab 93 2008 68
24. R. Rittmaster, R.G. Hahn, and P. Ray Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer Urology 72 2008 808
25. S.T. Page, J.K. Amory, and F.D. Bowman Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T J Clin Endocrinol Metab 90 2005 1502
26. S. Basaria, A.D. Coviello, and T.G. Travison Adverse events associated with testosterone administration N Engl J Med 363 2010 109